Wednesday, July 24, 2024

Fw: Ref.: (LML) Visible deformity after HD (leprosy) chemoprophylaxis among India tribals

 

 

Leprosy Mailing List –  July 24,  2024

 

Ref.:  (LML) Visible deformity after HD (leprosy) chemoprophylaxis among India tribals

From:  Jannine Ebenso, Brentford, UK


Dear Pieter and colleagues

 

Joel Almeida continues to make the same cause-effect argument about SDR-PEP. However, he never mentions that PEP is delivered in association with contact tracing and screening. (Be that SDR or the new regimens in the RCTs taking place in different countries).


All active case-finding initiatives show us the same thing – if you actively look for leprosy, you WILL find it – and if there are lots of hidden cases, then intensive screening will discover them! (cf Special Action Programmes for the Elimination of Leprosy (SAPEL) and Leprosy Elimination Campaigns (LEC) in the late 1990s).


The reverse is also true – if we don't look for leprosy, we will not find it – so have we checked that the lovely figures from Tamil Nadu reflect the reality? Again, I refer to findings from SAPEL and LECs. Areas that were recording very low numbers with mainly passive case finding, suddenly found many times more new cases with intensified case-finding. I believe that Dr Benedict Quao has also reported similar findings in recent surveys in Ghana. In my own experience with SAPEL and LEC in SE Nigeria, the MB and disability rates were very high – but from the patients' history, the new cases were infected and developed the disease many years previously.


In the non-PEP states referred to by Joel Almeida – is intensive contact tracing and screening taking place too?


Has Joel Almeida looked at the number of people screened over the same number of years to see if the high MB numbers and the high G2D numbers might actually be 'backlog cases' after years of not looking for leprosy? (like our own experience in Nigeria). In that case, SDR-PEP has nothing to do with it. Newly diagnosed, does not mean newly acquired.


My response is not in defence of SDR-PEP, nor do I want to disrespect anyone – I merely ask are other factors that have not been presented in Joel Almeida's argument? (Dr Ben Naafs also asks for other things to be considered, in his LML post of 13 July)

 

Regards


Jannine Ebenso

The Leprosy Mission International, Brentford, UK


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/d2e50bb8-bc93-4227-a23f-db1fde107e79n%40googlegroups.com.


From: Leprosy Mailing List <leprosymailinglist@googlegroups.com>
Sent: 24 July 2024 16:05
To: Leprosy Mailing List <leprosymailinglist@googlegroups.com>
Subject: Ref.: (LML) Visible deformity after HD (leprosy) chemoprophylaxis among India tribals
 

 

Leprosy Mailing List –  July 24,  2024

 

Ref.:  (LML) Visible deformity after HD (leprosy) chemoprophylaxis among India tribals

From:  Jannine Ebenso, Brentford, UK


Dear Pieter and colleagues

 

Joel Almeida continues to make the same cause-effect argument about SDR-PEP. However, he never mentions that PEP is delivered in association with contact tracing and screening. (Be that SDR or the new regimens in the RCTs taking place in different countries).

All active case-finding initiatives show us the same thing – if you actively look for leprosy, you WILL find it – and if there are lots of hidden cases, then intensive screening will discover them! (cf Special Action Programmes for the Elimination of Leprosy (SAPEL) and Leprosy Elimination Campaigns (LEC) in the late 1990s).

The reverse is also true – if we don't look for leprosy, we will not find it – so have we checked that the lovely figures from Tamil Nadu reflect the reality? Again, I refer to findings from SAPEL and LECs. Areas that were recording very low numbers with mainly passive case finding, suddenly found many times more new cases with intensified case-finding. I believe that Dr Benedict Quao has also reported similar findings in recent surveys in Ghana. In my own experience with SAPEL and LEC in SE Nigeria, the MB and disability rates were very high – but from the patients' history, the new cases were infected and developed the disease many years previously.

In the non-PEP states referred to by Joel Almeida – is intensive contact tracing and screening taking place too?

Has Joel Almeida looked at the number of people screened over the same number of years to see if the high MB numbers and the high G2D numbers might actually be 'backlog cases' after years of not looking for leprosy? (like our own experience in Nigeria). In that case, SDR-PEP has nothing to do with it. Newly diagnosed, does not mean newly acquired.

My response is not in defence of SDR-PEP, nor do I want to disrespect anyone – I merely ask are other factors that have not been presented in Joel Almeida's argument? (Dr Ben Naafs also asks for other things to be considered, in his LML post of 13 July)

 

Regards

Jannine Ebenso

The Leprosy Mission International, Brentford, UK


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/d2e50bb8-bc93-4227-a23f-db1fde107e79n%40googlegroups.com.

Fw: Ref.: (LML) Does Rifampicin PEP for household contacts alter the risk of multibacillary HD?

 

Leprosy Mailing List –  July 24,  2024

 

Ref.:  (LML) Does Rifampicin PEP for household contacts alter the risk of multibacillary HD?

From:  Epco Hasker, Antwerp, Belgium


 

Dear Pieter,

 

I would like to respond to the posting by Joel Almeida on the LML on 23 June. He presents a sub group analysis of data from the PEOPLE trial on single dose rifampicin post-exposure prophylaxis (SDR-PEP) for leprosy. He compares arm 2, in which SDR-PEP was provided to household contacts, to arm 1, the comparator arm, in which no PEP was provided. The analysis is restricted to MB cases only and conclusions focus on SDR-PEP provided to household contacts. Indeed in arm 2 there were 42 incident MB cases versus 27 in arm 1, while total follow-up time was comparable between the two arms. Almeida then concludes that SDR-PEP has caused an increase in incidence of MB leprosy.

As can be seen from the trial profile figure presented in the article [1], only seven incident patients in arm 2 had received SDR-PEP. Out of those four were PB, three were MB. So even if the theory that SDR-PEP given to household contacts would increase the risk of developing MB leprosy, how could it ever explain the 39 MB cases in arm 2 that had not received any PEP?

In addition, SDR-PEP was provided to household contacts not only in arm 2 but also in arms 3 and 4 of the PEOPLE trial. In these arms numbers and proportions of MB incident cases were substantially lower than in arm 1 (19/68 in arm 3 and 13/44 in arm 4). If we run the individual model comparing those who did and did not receive SDR-PEP, restricted to household contacts only and with MB-leprosy as outcome, the incidence rate ratio among SDR-PEP recipients is still 0.49, though not statistically significant because of the much smaller study population (p=0.34).

I strongly recommend that this discussion is continued in the peer reviewed literature, where inconsistencies in argumentation would have been flagged by reviewers before publication.

 

Kind regards,

 

Epco Hasker

 

1. Hasker E, Assoumani Y, Randrianantoandro A, Ramboarina S, Braet SM, Cauchoix B, et al. Post-exposure prophylaxis in leprosy (PEOPLE): a cluster randomised trial. Lancet Glob Health. 2024;12(6):e1017-e26. doi: 10.1016/S2214-109X(24)00062-7. PubMed PMID: 38762282.


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/48cecbcc-f4f2-41da-a19f-f866dc008094n%40googlegroups.com.

Sunday, July 21, 2024

Fw: Ref.: (LML) Widukind Lenz and thalidomide

 

 

Leprosy Mailing List – July 21,  2024

 

Ref.:  (LML) Widukind Lenz and thalidomide

From:  Joel Almeida, Mumbai, India


 

 

Dear Pieter and colleagues,

 

Widukind Lenz has a special place in the history of epidemiology. He died on 25 Feb 1995.

 

"On November 11, 1961, a date he remembered well, he first began to suspect that the sedative Contergan (thalidomide) could be the cause of this 'new' malformation syndrome. Three days later, his suspicion turned into certainty and he communicated these observations to the manufacturer — Grünenthal — and recommended withdrawal of the agent. Only 13 days later, the company withdrew the drug from the market.

In the meantime, Lenz had communicated on the matter at the meeting of the Rheinisch-Westfälische Pediatrics Society in Düsseldorf, where he pointed out that fourteen mothers of children with this syndrome had taken a specific compound; of twenty mothers with 'normal' children, only one had taken the same compound (and that at the end of her pregnancy)."

 

Epidemiologists sometimes analyse facts. Sometimes the facts disclose an emergency affecting the integrity of human limbs. Then time is of the essence.

 

Joel Almeida


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/a59e3ba7-2b0b-4c3a-bab5-4b9e7d51b9b3n%40googlegroups.com.

Friday, July 19, 2024

Fw: Ref.: (LML) Visible deformity after HD (leprosy) chemoprophylaxis among India tribals

 

Leprosy Mailing List –  July 19,  2024

 

Ref.:  (LML)  Visible deformity after HD (leprosy) chemoprophylaxis among India tribals

From:  Ben Naafs, Munnekeburen, the Netherlands


 

Dear Editor,

 

I think I didn't make it clear in my criticism of Joel Almeida's previous email that I am not at all in favour of SDR or even 2 days of Rifampicin. My criticism was mainly that he used a not so good Brazilian article to support his opinion. As for the Indian data, they are better. 

 

I think it is indeed possible that more disability can occur in a period of 2 years after SDR-PEP. But even better is to compare it after 5-10 years. 

 

The possible cause is that if the patient is not given medication, the adaptive immune system can gradually upgrade to cured or downgrade to lepromatous. After giving medication, the patient suddenly is exposed to additional and different antigenic determinants, this upgrade response can be further enhanced by an enhanced immune system by the BCG. This leads to a T1R that needs to be diagnosed and treated. Otherwise you will indeed get damage.

 

I hope I make it clear what I meant.

 

regards

 

Ben

 

Note editor: we want to stress again that LML is an open forum. Please react, especially when some conclusions could be considered by some quite premature


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/758296b8-e58c-4913-a0c3-81c0070d2cbfn%40googlegroups.com.

Fw: Ref.: (LML) New Publications On Cross-Cutting Issues In NTDs. July, 2024.

 

 


Leprosy Mailing List –  July 19,  2024

 

Ref.:  (LML) New Publications On Cross-Cutting Issues In NTDs. July, 2024.

From:  Roos Geutjes and Sophie Vissers, Amsterdam, the Netherlands




 

Dear colleagues, 

The July newsletter edition is packed with practical materials and publications from the WHO, including the latest guidelines for the treatment of human African trypanosomiasis. This month's special edition focuses on Decolonization and Power Asymmetry in Global Health, offering plenty of thought-provoking content to ponder over the upcoming month.
 
In this newsletter, we offer a selection of the content that has been added to our platform. Please visit the website to access all new publications.

We are excited to announce that the InfoNTD website will soon have a fresh new look and feel! In the upcoming weeks, you will find two new sections in the navigation menu: News & Events and Online Courses. Additionally, the search functionality has been further optimized for a better user experience. Keep an eye on the website and let us know what you think of these new developments!

Stay up to date on the opportunities for learning, networking and growth by reviewing the news articles, events and call for proposals at the end of the newsletter.

 

Warm regards,

Roos Geutjes and Sophie Vissers

www.InfoNTD.org
info@InfoNTD.org
 





Practical materials





Guidelines for the treatment of human African trypanosomiasis (WHO manual)


Target product profile for a diagnostic test to confirm cure of visceral leishmaniasis (WHO technical brief)


One Health Toolkit (Internews Health Journalism Network toolkit)


Integrated Campaign Digitization (ICD) Toolkit (Health Campaign Effectiveness Coalition toolkit)


Accessibility GO! A Guide to Action (CBM guideline)


Strengthening climate-resilient health systems: opportunities and challenges at policy and facility level (ReBUILD for Resilience & Oxford Policy Management webinar)


Reducing stigma and discrimination faced by children and adults with disabilities (COSP17 Side Event recording)


CBM Global and OPD partners share climate advocacy journey so far (Sensing Climate Conversation Series recording)


Infectious Disease Data Observery Data Repository (IDDO Database)


Case report form for uncomplicated visceral leishmaniasis (DNDI & IDDO form)


Chagas disease case report form (IDDO form)


A Guide to the Clinical Management of Vipera Snakebite in Italy (Guideline)


Elimination Exchange (Global Institute for Disease Elimination Podcast Series)


Innovative Strategies to Combat Neglected Tropical Diseases in Kenya (Amref Health Africa podcast)





Decolonization & power asymmetry



Reimagining the language of engagement in a post-stakeholder world
Reed MS, Merkle BG, Cook EJ, et al. Sustainability Science. Springer Science and Business Media LLC. 2024; 19 (4) : 1481-1490.


Podcasts as a tool to disrupt knowledge hierarchies and silos to decolonize global health
van Niekerk L, Topp SM, Pasternak N, et al. Nature Medicine. Springer Science and Business Media LLC. 2024; 30 (5) : 1227-1228.


Decolonial framework for applying reflexivity and positionality in global health research
Naidu T, Gingell G, Zaidi Z. Global Health Promotion. SAGE Publications. 2024.


Towards authentic institutional allyship by global health funders
Oti SO, Robinson J, Pai M. PLOS Global Public Health. Public Library of Science (PLoS). 2024; 4 (3) : 1-4.


Rethinking Global Health
Burgess RA. Routledge. 2024.


Missing in action: a scoping review of gender as the overlooked component in decolonial discourses
Nassiri-Ansari T, Rhule ELM. BMJ Global Health. BMJ. 2024; 9 (4) : 1-9.


Against Decolonisation: Taking African agency seriously.
Táíwò O. Hurst Publisher. 2023.






Other new publications



Annual report 2023: Expanded Special Project for Elimination of Neglected Tropical Diseases
World Health Organization, Regional Office for Africa, Control of Neglected Tropical Diseases team. 2024.


Report of the sixth meeting of the WHO Diagnostic Technical Advisory Group for Neglected Tropical Diseases: Geneva, Switzerland, 14–15 February 2024
World Health Organization, Control of Neglected Tropical Diseases team, Diagnostics Technical Advisory Group team. 2024.


WHO Alliance for the Global Elimination of Trachoma: progress report on elimination of trachoma, 2023
World Health Organization. 2024.


Anticipatory action for climate-sensitive infectious diseases: Latin America Regional Assessment
Red Cross Red Crescent Climate Centre. 2024.


Overview and Summary of GLIDE's Inaugural Symposium: Integrated Approaches to Disease Elimination
Global Institute for Disease Elimination. 2024.


Capacitating One Health in Eastern and Southern Africa: Experiences and Implications in Ethiopia
Tadesse Y, Mor S, Knight-Jones T, et al. 2024.


Active Community-Based Case Finding of Endemic Leishmaniasis in West Bengal, India.
Guha S, Sardar A, Misra A, et al. Journal of epidemiology and global health. 2024.


Leveraging wastewater-based epidemiology to monitor the spread of neglected tropical diseases in African communities.
Ofori B, Agoha R, Bokoe E, et al. Infectious diseases (London, England). 2024.


Using Medical Illustration to Improve Understanding and Communication of Skin Neglected Tropical Diseases
Butler J. Faculty of Health and Medical Sciences. University of Surrey. 2023. 


Integrating eye care into primary healthcare in Nigeria: Challenges of the primary healthcare workforce
Christian BN, Shomuyiwa DO, Christian NG, et al. Public Health Challenges. Wiley. 2024; 3 (2) : 1-7.


GD07 Skin neglected tropical diseases and global health: migration and integration beyond borders
Parajuli N. British Journal of Dermatology. Oxford University Press (OUP). 2024.


Availability of published evidence on coverage, cost components, and funding support for digitalisation of infectious disease surveillance in Africa, 2003-2022: a systematic review.
Kaburi B, Harries M, Hauri A, et al. BMC public health. 2024; 24 (1) : 1-15.


Buruli ulcer, tuberculosis and leprosy: Exploring the One Health dimensions of three most prevalent mycobacterial diseases: A narrative review
Spiliopoulos O, Solomos Z, Puchner KP. Tropical Medicine & International Health. Wiley. 2024.


Accuracy, acceptability and feasibility of photography for use in trachoma surveys: a mixed methods study in Tanzania
Bisanzio D, Butcher R, Turbé V, et al. International Health. Oxford University Press (OUP). 2023; 16 (4) : 416-427.


Effects of cutaneous leishmaniasis on patients' quality of life.
Yizengaw E, Nibret E. BMC infectious diseases. 2024; 24 (1) : 1-5.


Navigating the Path to Elimination: Lessons from Lymphatic Filariasis and Trachoma Dossiers
USAID , Act to End NTDs East , RTI International . Technical Brief Series. 2024.


An integrated inventory of One Health tools: Mapping and analysis of globally available tools to advance One Health
Behravesh CB, Charron DF, Liew A, et al. CABI One Health. CABI Publishing. 2024.


AI sees an end to filariasis
Gaunt MW, Crainey JL, Kamhawi S. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2024; 18 (7) : 1-3.
Link to download AI tool. 
Link to youtube video.



Report of the fifth WHO stakeholders meeting on gambiense and rhodesiense human African trypanosomiasis elimination, Geneva, Switzerland, 7–9 June 2023
World Health Organizaiton, Control of Neglected Tropical Diseases team. 2024.


Dracunculiasis eradication: global surveillance summary, 2023
World Health Organization, Control of Neglected Tropical Diseases team. 2024.


Report of the first meeting of the Global Onchocerciasis Network for Elimination: Saly, Senegal, 1-2 November 2023
World Health Organization, Control of Neglected Tropical Diseases team, Global Onchocerciasis Network for Elimination team. 2024.


Understanding the burden of poor mental health and wellbeing among persons affected by leprosy or Buruli ulcer in Nigeria: A community based cross-sectional study
Ossai EN, Ekeke N, Esmai-Onyima A, et al. PLOS ONE. Public Library of Science (PLoS). 2024; 19 (6) : 1-15.


Vascular Damage in Neglected Tropical Diseases
Silvestri V, Mushi V, Ngasala B. Springer Nature Switzerland. 2024.


Capacities and needs of health care facilities for schistosomiasis diagnosis and management in elimination settings.
Ndum N, Trippler L, Mohammed U, et al. Parasites & vectors. 2024; 17 (1) : 1-14.


Improving patient-centered mental health promotion in primary care in vulnerable communities through mindfulness training in Rio de Janeiro, Brazil
Teixeira DS, Fortes S, Kestenberg C, et al. Frontiers in Medicine. Frontiers Media SA. 2024.


DeepLeish: a deep learning based support system for the detection of Leishmaniasis parasite from Giemsa-stained microscope images.
Tekle E, Dese K, Girma S, et al. BMC medical imaging. 2024; 24 (1) : 1-12.


Artificial Intelligence in Dermatopathology: updates, strengths, and challenges.
Cazzato G, Rongioletti F. Clinics in dermatology. 2024.


Improving access to eye care services in Ghana using community health structures
Ofosu A, Osei I, Hagan M, et al. African Vision and Eye Health. AOSIS. 2024; 83 (1) : 1-9.


A climatic suitability indicator to support Leishmania infantum surveillance in Europe: a modelling study
Carvalho BM, Maia C, Courtenay O, et al. The Lancet Regional Health - Europe. Elsevier BV. 2024.


Media advocacy and the actualization of "Vision 2020: the right to sight" in Nigeria
Gambo S, Shem W, Essien CF. REVISTA ESPAÑOLA DE COMUNICACIÓN EN SALUD. Universidad Carlos III de Madrid. 2024; 15 (1) : 86-97.


What is the state of the art on traditional medicine interventions for zoonotic diseases in the Indian subcontinent? A scoping review of the peer-reviewed evidence base
Asaaga FA, Tomude ES, Rahman M, et al. BMC Complementary Medicine and Therapies. Springer Science and Business Media LLC. 2024; 24 (1) : 1-19.


The role of social media in public health awareness during times of war in Sudan: snakebites and scorpion stings
Baleela RMH, Mohammad A, Saeed SAK. BMC Public Health. Springer Science and Business Media LLC. 2024; 24 (1) : 1-18.


Strengthening the collection, interpretation and use of data to target expansion and integration of case detection and management interventions against neglected tropical diseases.
Simpson HN. Faculty of Infectious and Tropical Diseases. London School of Hygiene & Tropical Medicine. 2024.


Rocky Mountain spotted fever is a neglected tropical disease in Latin America.
Álvarez-Hernández G, Paddock C, Walker D, et al. PLoS neglected tropical diseases. 2024; 18 (7) : 1-7.


Dental auxiliaries' knowledge, attitude, and practices regarding noma prevention: A cross-sectional study in Northwestern Nigeria
Bala M, Kaura MA, Tsafe AB, et al. Journal of Oral Research and Review. Medknow. 2024; 16 (2) : 91-96.






News & Events



Kenya expands schistosomiasis fight to children under five (news article)


Funding to study neglected tropical diseases and develop new technologies is very limited (news article)


Call for research proposals on skin-related Neglected Tropical Diseases (NTDs) CfP-NTD2025 
The Diorapthe foundation will support preclinical, clinical and operational research. Deadline for submission is October 4 (18:00 CEST) 2024. For all the information please check
the call for research proposal document.


PAHO's Initiative for the elimination of communicable diseases
Theme: "Advancing the Agenda - Achievements and Future Directions"
July 31, 2024; 9:30 am - 11:10 am (EDT); webinar.
This webinar aims to share knowledge and best practices related to the PAHO Initiative, a strategic effort by PAHO and countries in the Americas to eliminate over 30 communicable diseases and related conditions by 2030.
Please make sure to register in advance.


The Royal Society of Tropical Medicine & Hygiene hosts several events including their annual meeting, webinars with interesting guests, events foccused on early career researchers and a regional meeting taking place in Nigeria focussing on West-Africa. Please check out their website for all the events.


Africa Evidence Week 2024: Celebrating EIDM in Africa
August 19-23, 2024; online event.
Africa Evidence Week 2024 is a virtual celebration of African EIDM and the decision-makers who make it possible. To participate you have to submit live in-person events, live online events, pre-recorded webinars,  Twitter chats, blog posts, video content, publications or any other digital content aligned to the objectives of the event. The deadline for submission is July 19 (17:00 PM SAST) 2024.


The 7th CBR/CBID Africa Conference 
September 2-5, 2024; Entebbe, Uganda. 
This three-day CBR/CBID Africa conference will provide a platform for various stakeholders to come together, exchange ideas on the role of CBR/CBID in promoting disability inclusive development. Early Bird Registration is until August 15.


Bridge CRPD-SDGs Pacific Region Module 1
September 12-18, 2024; in-person training; Fiji.
The Pacific Disability Forum, the International Disability Alliance (IDA), and the International Disability and Development Consortium invite people with disabilities from the Pacific region to join the Bridge CRPD-SDGs training. The countries include Papua New Guinea, Fiji, Solomon Islands, Vanuatu, Samoa, Cook Islands, Tuvalu, Niue, Micronesia, Kiribati, Marshall Islands, Palau, Nauru. Check how to apply on their website. The deadline for application is July 20 2024.


Swiss TPH Hybrid Symposium: Defining the Noma Research Agenda
September 20, 2024; hybrid event; Allschwil, Switzerland.
Join the symposium to unite efforts to better understand, prevent and treat noma. The symposium is co-organised with Elysium, the first noma survivors' association. For updates check their website.


NNN Conference 2024
October 1-3, 2024; Kuala Lumpur, Malaysia.
The NNN Annual Conference 2024 will take place from 1st of October - 3rd of October, 2024, in Kuala Lumpur Malaysia. The theme for the conference is: "Collaboration for Change: Fostering Global Equity and Strengthening Community Engagement in NTDs." The Early Bird registration is now open.
You can find more information by clicking here.


UNC Water and Health Conference 
October 14-18, 2024; hybrid event; Chapel Hill, United States of America.
The annual UNC Water and Health Conference reflects Water Institute's commitment to improving public health by achieving universal access to safe drinking water, sanitation and hygiene (WaSH) services that are safe, affordable and sustainable. In-person registration is open and online participation registration is coming soon.


Unite Global Summit – Building Trust for Global Health. Parliamentarians' Leadership for Change
October 16, 2024; in-person event; Berlin, Germany. 
The UNITE Global Summit 2024's agenda will be divided into the main pillars: human rights & equitable access to health, global health architecture & security, strenthening of healthcare systems and sustainable financing for health. The event is the world's leading Forum for forging partnerships between parliamentarians and leaders from the global health community. Early bird registation until July 31.


Global Eye Health | Online Short course (LSHTM)
November 11-14, 2024; Online.
The goal of the workshop will be to familiarise participants with: Public eye health principles, the aims, objectives and strategies of Universal Eye Health Coverage. The course programme will also look at survey methodologies and strategies for control of the major eye health-related diseases. Application deadline for scholarships and general application is 20th of July.


Conference on Neglected Tropical Diseases 2024
November 14-16, 2024, Nairobi; Kenya.
The 1st edition of the Conference on Neglected Tropical Diseases, organized by AME is tentatively scheduled from 14-16 November in Nairobi, Kenya, as a hybrid meeting. The abstract-driven conference proposes a platform to disseminate new advanc
ements, real-world data, implementation challenges, and novel governing models to discuss and generate solutions for cross-cutting topics and ultimately reduce the disease burden and societal impact of NTDs. This proposal supports the progress in foundational pillars of the WHO Roadmap by facilitating evidence-based program implementation, leveraging the cross-cutting approach, and providing a forum to discuss a paradigm shift toward country ownership of elimination programs.



One Health Clinic at a Time, Malawi Transforms the Patient Experience (news article)


GHS pushes for the inclusion of elephantiasis patients in health insurance  (news article)


Request for Proposals | Robert Carr Fund  
The Robert Carr Fund invites global and regional civil society networks and consortia of networks led by, and/or serving inadequately served populations to apply for a grant to support their core funding and activity needs for a three-year period (2025-2027). Deadline for proposal submission via online application portal 22 July 2024 12:00 (noon) CET. 


Call for Applications of the Joint EMRO/TDR Impact Grants for regional priorities focused on implementation research in infectious diseases of poverty.
Funding: US$ 8000–$10 000 per grant. 
Deadline for submission September 15 (17:00 CEST) 2024. Only applicants from the WHO Eastern Mediterranean Region are eligible. For other criteria and information please check the website.


IX Reunión ChagasLeish y XIX Simposio PECET Theme: "avances en la investigación de enfermedades tropicales"
August 15-16, 2024; in-person event; Medellín, Colombia. 
The event aims to disseminate advances and research outcomes in leishmaniasis and Chagas disease, fostering new research questions and promoting multidisciplinary collaboration. Check their website for information regarding registration.


BSP Autumn Symposium 2024 - Highlighting female and male genital schistosomiasis
September 4-5, 2024; in-person event; London, United Kingdom.
The symposium will bring together clinicians and biologists interested in discussing knowledge gaps concerning the natural history of the disease, its diagnostic challenges as well as clinical management. The meeting will also encourage a diversity of speakers and early career researchers who shall give invited/open oral presentations and interact further during the open poster sessions. The deadline for abstract submission is August 1 and registration is expected to open shortly.


Conference on Tropical Medicine and Global Health
September 19-21, 2024; Dusseldorf, Germany.
Some of the topics: Emerging Infectious Diseases and Pandemic Preparedness I Malaria update: prophylaxis and resistance I New vaccines I High Consequence Infectious Diseases I Interdisciplinary health concepts I Climate change and health I Non Communicable Diseases I Innovative diagnostics I Big Data and Artificial Intelligence in Tropical Medicine I Clinical cases I Update Tropical and Travel Medicine (incl. Refresher course Travel Medicine) I Sustainable travel I Clinical and scientific training and career opportunities. Early bird registration until June 30.


COR-NTD Meeting for the Pacific Islands 
September 25-26, 2024; in-person event; Brisbane, Australia. 
The goal of this meeting is to bring together key stakeholders to address how to eliminate lymphatic filariasis, scabies, trachoma, leprosy and other NTDs from the region. We believe that together we can eliminate and maintain elimination of these NTDs. Registration will open soon.


Conference on control strategies for schistosomiasis in Madagascar
October 11, 2024; Antananarivo, Madagascar.
The aim of the conference is to fuel the discussion and strengthen the networks between Malagasy stakeholders and policy makers, international experts, health professionals and scientist to work together to reach equity through elimination. Registration deadline is the 15th of September 2024.


2024 Annual Meeting of National NTD Programme Managers 
Theme: "Innovating for acceleration: Pathways to NTD Elimination"
October 15-17, 2024; save the date.
Updates will follow but you can ask your questions by e-mailing to
ESPENAFRO@who.int 


4th International Conference on Indigenous Knowledge Systems and Practices Theme: "The Politics of Knowledge"
October 22-24, 2024; in-person event; Cape Town, South Africa. 
This conference serves as a platform for engaging critically with knowledge-making and the ​philosophical underpinnings of what it means to produce knowledge in the world ​today. Registration is expected to open shortly and the deadline for abstract submission is July 31.


ASTMH - Annual Meeting 
November 13-17, 2024; in-person event; Louisiana, New Orleans
The scientific program is designed for researchers, professors, government and public health officials, military personnel, travel clinic physicians, practicing physicians in tropical medicine, students, and all healthcare providers working in the fields of tropical medicine, hygiene, and global health. Invitation letters for travel approval assistance are available
here. Registration is open and the early rate deadline is September 30. The deadline for late-breaker abstracts is July 30.


125th Anniversary Scientific Symposium
November 25-27, 2024; hybrid event; Liverpool, United Kingdom.
Topics throughout the three-day event will include Lung Health and TB, HIV, Malaria, Neglected Tropical Diseases, Resilient Health Systems, Resistance Research and Management, the Impact of Climate Change on Global Health, Health Policy and Systems Research, and Maternal, Newborn and Child Health. Registration is open.


12th TEPHINET Scientific Conference and the Global Field Epidemiology Partnership Forum 
June 2-5, 2025; Berlin, Germany.
For more information, please visit the TEPHINET Website. The deadline for abstract submission is September 30, 2024. 





GDPR & the InfoNTD newsletter

 
New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our
privacy statement and mailing list.

InfoNTD sends out monthly e-mails with an overview of recent publications on NTDs and cross-cutting issues. The purpose of this activity is to keep subscribers up to date.

InfoNTD will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can
update your preferences or unsubscribe from this list at any time.







LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/4d96e12e-166a-48a4-baba-601cdae0f1f9n%40googlegroups.com.